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Abstract
Objective To determine the clinical effectiveness of wound edge
protection devices in reducing surgical site infection after abdominal
surgery.
Design Multicentre observer blinded randomised controlled trial.
Participants Patients undergoing laparotomy at 21 UK hospitals.
Interventions Standard care or the use of a wound edge protection
device during surgery.
Main outcome measures Surgical site infection within 30 days of
surgery, assessed by blinded clinicians at seven and 30 days and by
patient’s self report for the intervening period. Secondary outcomes
included quality of life, duration of stay in hospital, and the effect of
characteristics of the patient and operation on the efficacy of the device.
Results 760 patients were enrolled with 382 patients assigned to the
device group and 378 to the control group. Six patients in the device
group and five in the control group did not undergo laparotomy. Fourteen
patients, seven in each group, were lost to follow-up. A total of 184
patients experienced surgical site infection within 30 days of surgery,
91/369 (24.7%) in the device group and 93/366 (25.4%) in the control
group (odds ratio 0.97, 95% confidence interval 0.69 to 1.36; P=0.85).
This lack of benefit was consistent across wound assessments performed
by clinicians and those reported by patients and across all secondary
outcomes. In the secondary analyses no subgroup could be identified
in which there was evidence of clinical benefit associated with use of
the device.
ConclusionsWound edge protection devices do not reduce the rate of
surgical site infection in patients undergoing laparotomy, and therefore
their routine use for this role cannot be recommended.
Trial registration Current Controlled Trials ISRCTN 40402832
Introduction
Surgical site infection is one of the most common postoperative
complications, occurring in at least 5% of all patients undergoing
surgery and 30-40% of patients undergoing abdominal surgery,
depending on the level of contamination.1 2 Development of a
surgical site infection has a large impact on mortality and
morbidity as well as healthcare costs.3 4 In the United Kingdom,
length of stay in hospital is typically doubled and additional
costs per patient of between £814 and £10 523 (€950 ($1237)
and €12 300 ($16 000)) have been estimated, the variability
depending on the type of surgery and the severity of the
infection.5-7 The ancillary costs from time off work, reduced
health related quality of life, dissatisfaction in patients, and
litigation costs for the healthcare provider have been explored
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less extensively, but the little evidence available confirms a
detrimental effect.8
As most infections are the result of wound contamination by
endogenous bacteria from the patient’s skin, mucous
membranes, or hollow viscera, the concept of using a physical
barrier to cover the cut edges of the wound has been revisited
by surgeons many times over the past half century. This
protection can take the form of a wound edge protection device
or “wound guard” that is inserted into the wound for the duration
of the operation. There are several different devices on the
market but they have the same basic design—a semirigid plastic
ring placed into the abdomen through the laparotomy wound to
which an impervious drape is circumferentially attached. This
plastic drape comes up and out of the wound on to the skin
surface, thus protecting the cut edges of the wound (fig 1)⇓.
Wound edge protection devices create a physical barrier between
the abdominal wound edges and viscera, visceral contents,
contaminated instruments, and gloves, thereby reducing
accumulation of endogenous and exogenous bacteria on the
wound edges. There have been six single centre and one
multicentre trial, totalling around 1300 patients, which showed
benefit from the use of a device and reporting a reduction in
infections from 12-25% down to as low as zero in some series.9-15
Despite this their use is not discussed in the current UK clinical
guidelines and they have not become established in routine
clinical practice.
We assessed the clinical effectiveness of wound edge protection
devices in reducing rates of infection at the site of surgery in
patients undergoing open abdominal surgery to evaluate the
impact on patients’ health related quality of life and length of
hospital stay. We also carried out a cost effectiveness analysis,
which will be reported elsewhere.
Methods
Study design and patients
The ROSSINI (Reduction Of Surgical Site Infection using a
Novel Intervention) trial was a prospective, multicentre, observer
blinded, randomised controlled trial with stratification according
to baseline infection risk.16 It was conducted from February
2010 to January 2012 at 21 National Health Service (NHS)
hospitals across the UK.
This investigator initiated trial was conceived by the West
Midlands Research Collaborative, a trainee led surgical research
group who designed, disseminated, and managed the trial in
conjunction with the Primary Care Clinical Research and Trials
Unit and the Birmingham Clinical Trials Unit at the University
of Birmingham.
Patients aged over 18 undergoing laparotomy for any surgical
indication through any major incision in both elective and
emergency settings were eligible for enrolment. Laparoscopic
or laparoscopic assisted procedures were excluded, as were
patients who had undergone a previous laparotomy within three
months.
Randomisation and masking
Enrolled patients were randomly assigned through a concealed
centralised secure web based system in a 1:1 ratio to either the
control arm (standard intraoperative care) or the intervention
arm (standard intraoperative care plus use of a wound edge
protection device during the intra-abdominal part of the
operation). Randomisation was performed when the patient was
in the anaesthetic room immediately before surgery by using a
secure online system provided by the University of Birmingham.
To help match the two arms, randomisation was stratified
according to the urgency of surgery, likelihood of opening a
viscus, and likelihood of creating a stoma, with the use of a
minimisation procedure. The in theatre surgical teamwere aware
of arm allocation but only after induction of anaesthesia. No
information about arm allocation was recorded in the clinical
or operation notes, and the patient, ward staff, and clinicians
undertaking the reviews of postoperative wounds were fully
blinded to the group assignments.
Surgeons were free to undertake their other usual intraoperative
interventions if they wanted, including their choice of antibiotic,
skin preparation agent, use of adhesive incise drapes, and/or
towels on the wound edges; these details were prospectively
recorded and formed part of a planned secondary analysis. The
device used (3M Steri-Drape Wound Edge Protector) was
available in three different sizes at each site to enable an
appropriate sized device to be selected for the laparotomywound
if the patients was allocated to the intervention arm.
Efficacy outcomes
The primary endpoint was occurrence of superficial surgical
site infection within 30 days after the operation. Diagnosis was
based on criteria developed by the Centers for Disease Control
(CDC).17All wound assessors were experienced in the appraisal
of postoperative wounds and were provided with standardised
criteria and instructions regarding assessment. Centralised
meetings to update investigators were held throughout the trial,
included training in wound assessment, and each unit received
a site visit on opening, which included training of local
investigators. Additional standardisation of assessment was
provided with a dedicated online e-learning module and quiz,
developed for this study to minimise variability between
assessors.
Secondary endpoints included health related quality of life,
length of hospital stay, cost effectiveness, and the clinical
efficacy of the device in relation to the degree of contamination,
patient comorbidities, and operative demographics. This
information was recorded contemporaneously on standardised
clinical report forms.
Data on health related quality of life were collected at baseline,
five to seven days, and 30 days with the validated EuroQol
(EQ-5D 3L) tool.18 Questionnaires were paper based and
completed by the patient. The principal analysis was the change
in overall health related quality of life assessed by the EQ-5Dindex
score at 30 days.19 Data on resource use were collected for 30
days according to a standardised protocol.
Procedures
Preoperative evaluation included the prospective assessment
and recording of demographic data related to the patient and
comorbidity. Operative details, including any deviation from
allocation, were recorded immediately after the operation.
A trained blinded reviewer formally assessed the wound on day
five to seven or at discharge if the patient left hospital earlier.
A second formal wound reviewwas performed at 30 to 33 days,
which involved the patient returning to hospital for a physical
review of the wound. At this same visit, patients also completed
a self reported questionnaire with the study investigator to
identify any occurrence of surgical site infection during the
intervening period between the two clinician assessments. The
questionnaire was based on the Health Protection Agency
surgical site infection surveillance system (HPA SSISS), which
is also based on the original CDC definitions. To maximise
completeness of follow-up, trial research staff carried out home
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visits to the small number of patients who were unable to return
to hospital for their second formal wound review because of
infirmity or geographical distance.
Investigators who were blinded to the group assignments
assessed the seriousness of all reported adverse events and
determined if they were related to the study and/or the
intervention.
Statistical analysis
We hypothesised that the use of wound edge protection devices
in adults undergoing laparotomywould result in a 50% reduction
in the infection rate based on a conservative appraisal of
evidence available from other trials.10 11Assuming a conservative
baseline infection rate of 12%,20 21 we needed 710 patients to
confirm this effect with a two sided α of 5% and 80% power.
The recruitment target was extended to 750 patients to
accommodate a potential 5% dropout rate. Results were analysed
according to intention to treat. Analyses were performed with
SAS version 9.2 and R Statistical software (v2.14). Dichotomous
outcomes (incidence of surgical site infection within 30 days)
were analysed with the use of non-linear mixed models, which
included stratification variables (plan to open a viscus, create a
stoma, and elective v urgent surgery) as patient level covariates
and surgeons as random effects. The difference in EQ-5Dindex
score by treatment group at 30 days was assessed with a mixed
model that included baseline EQ-5Dindex score and stratification
variables as patient level covariates and surgeons as random
effects. Time to discharge from hospital was estimated according
to the Kaplan Meier method and analysed with the use of Cox
proportional hazard model, which included stratification
variables as covariates. The initial model was developed in SAS
v 9.2, with surgeons subsequently included as random effects
with the frailty term in R Statistical Software. Complete case
analyses were undertaken for the data on health related quality
of life. For those patients who died within 30 days of surgery
we carried forward the last available wound assessment, unless
no information was available in which case they were treated
as lost to follow-up.
Results
Study participants
From February 2010 to January 2012 we enrolled 760 patients
from 21 UK centres and randomised 382 to the wound edge
protection device group and 378 to the control group (fig 2).⇓
Of these, 376 and 373, respectively, underwent laparotomy and
were included in the study. Seven patients in each group were
subsequently lost to follow-up. Patients’ demographics (table
1)⇓, comorbidities, and operation characteristics (table 2)⇓,
including degree of contamination and NNIS risk index, did not
differ substantially between the two groups at baseline.
Surgical site infections
In total, 184 patients experienced a surgical site infection within
30 days of surgery, 91/369 (24.7%) in the device group and
93/366 (25.4%) in the control group (odds ratio 0.97, 95%
confidence interval 0.69 to 1.36; P=0.85) (table 3).⇓ The results
were consistent across the assessments made at different time
points within the study and by different observers, with both
the formal assessments of wounds by clinicians and the patients’
self reported data showing no difference on post hoc analysis
(fig 3)⇓. Furthermore, we observed no significant reduction in
infection rate within 30 days by treatment group in any of the
prespecified subgroup analyses (fig 4).⇓
Deviations from protocol and sensitivity
analyses
A wound edge protection device was used in four patients
randomised to the control arm and was not used in 29 patients
randomised to receive the device: in 11 cases the device was
unavailable or of inappropriate size for the procedure, in six
cases the nature of the surgery or the peritoneal cavity prevented
insertion, in 12 cases the surgical team forgot to use the device.
A post hoc sensitivity analysis was undertaken to explore the
effect of treatment cross over on the estimate of effectiveness
of the device. In this “best case scenario” analysis (in which a
maximal benefit from use of device is assumed), all patients
allocated to the control group but in whom a device was used
were assumed to have had an infection within 30 days,
conversely those patients randomised to device use in whom a
device was not used were assumed to have had no event. In this
extreme case results of the analysis of the effect of the device
were still non-significant (odds ratio 0.77, 95% confidence
interval 0.54 to 1.09; P=0.14). Further exploratory analyses
were also undertaken to assess any potential learning curve
effects with use of the device. We found no significant
association between the rate of surgical site infection and
number of wound edge protection devices used, both at unit and
individual surgeon level.
Secondary outcomes
We observed no significant difference in health related quality
of life (mean difference in EQ-5D score 0.001, 95% confidence
interval −0.043 to 0.046; P=0.95), and the time to first discharge
from hospital was comparable across treatment groups (hazard
ratio 1.03, 95% confidence interval 0.88 to 1.19; P=0.82). There
were no significant differences in healthcare use between the
trial arms in both secondary and primary care settings.
Eleven patients in each group were readmitted to hospital with
a surgical site infection, the remaining infections were managed
in the community or before discharge from their index
admission.
None of the prespecified secondary analyses exploring the
efficacy of the wound edge protection device in reducing the
likelihood of infection at the site of surgery according to degree
of abdominal contamination, patient comorbidity, duration of
surgery, or grade of surgeon closing the wound showed any
significant difference (table 2 and fig 4).⇓⇓
Adverse events
In total 20 patients died within 30 days of surgery (12 in control
group; eight in device group). No adverse events associated
with the use of the device were reported.
Overall effects of infection at the site of
surgery (both arms)
Patients without an infection had a significantly shorter duration
of initial stay in hospital (median days 9 (interquartile range
6-13) in control group and 8 (6-14) in device group) than those
with an infection (10 (7-22) and 10 (7-20)).
The 184 patients who developed a surgical site infection
consumed significantly more resources in the primary care
setting compared with the uninfected patients, reflected in the
mean number of interactions with community healthcare
professionals (general practitioner, district nurse, practice nurse):
mean 8.03 (SE 0.66) in the patients with infection and 3.26
(0.28) in the patients without (P<0.001). EQ-5D scores also
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indicated a 11% reduction in health related quality of life at 30
days in the patients who developed an infection (P<0.001).
Discussion
The ROSSINI trial has found that the use of wound edge
protection devices during laparotomy does not result in a
reduced rate of surgical site infection. This finding was
consistent across a range of patient subgroups and for early and
late infection. The use of resources, both in hospital and
subsequently in the community, was comparable across both
arms of the study. These findings differ from results of most
previous studies and from two published meta-analyses.22 23 Of
the previous studies, only twoweremulticentre and all displayed
considerable potential risk of bias. These limitations have been
expressed in the expert literature and the need for a large
multicentre trial identified.24
The reasons behind the variance between the ROSSINI trial and
several previous published studies are uncertain. The two
previously published multicentre randomised controlled trials
reported from a combined total of six units and 270 patients.
Nystrom and colleagues, concurring with ROSSINI findings,
reported data from 140 patients undergoing elective colorectal
surgery at two centres and found no benefit from the use of a
device (rate of infection of 10% in the intervention arm and 9%
in the control group).25 More recently, however, Reid and
colleagues reported on 130 elective colorectal resections at four
Australian centres and found a significant reduction in surgical
site infection in the device arm, with 3/64 (4.7%) developing
infection versus 15/66 (22.7%) in the control arm (P=0.004).15
Our trial reported included 760 patients across 21 centres (62%
colorectal operations) and found no demonstrable benefit for
any subgroup of patients.
Strengths and weaknesses
One concern, particularly in an interventional study, is blinding
the assessment to avoid bias. We incorporated several design
points to overcome this, including electronic randomisation
(including a minimisation procedure), group concealment,
blinding of wound assessors and patients, and a robust quality
assured follow-up protocol including training in wound
assessment. Previous studies of wound edge protection devices
have not undertaken all such measures.
The patient groups in our study were well matched with no
significant over-representation of any patient or operative
characteristic in either arm. At 25.4%, the baseline infection
rate was significantly higher than the conservative 12% predicted
baseline rate. This provided increased power to detect potential
benefit. Traditionally quoted rates of infection have previously
been based on passive and retrospective surveillance and so
were prone to under-reporting. The apparent incidence of
infection increases significantly, at least doubling in some
reports, when outpatient follow-up is undertaken and/or
appropriately trained wound observers are used.7-28 Recent UK
data have reported that the time to onset of infection after
gastrointestinal operations is eight to nine days (interquartile
range 5-12 days)29 and as such will often present after the patient
has been discharged from hospital. The higher infection rates
(across all sites in our trial) are therefore likely to be related to
the policy of more intensive and longer follow-up. Our infection
rate is consistent with the rates in several recent studies that
also used active wound monitoring and reviews after discharge
for colorectal surgery, with reported rates of 25%,30 25.3%,31
and 24.9%.32. The fact that the length of hospital stay, use of
health resources, and health related quality of life were all
significantly and detrimentally affected in patients with a
diagnosis of an infection suggests that these patients were truly
affected by a condition that impacted on their postoperative
recovery and counters the proposition that that the trial processes
might have overdiagnosed occurrence of infection at the site of
surgery, masking an underlying benefit.
A further notable finding in our trial is the higher than expected
infection rate in clean and clean-contaminated operations, which
shows little difference to the other contamination groups and is
in contrast to routinely presented data. Closer examination of
these groups found that the combined infection rate for clean
and clean-contaminated patients at the wound review on day
five to seven was only 6.5% (compared with 12.1% at this stage
for the contaminated and dirty wounds). Most infections at the
site of surgery in these patients were therefore diagnosed after
discharge. This could suggest that the apparently lower infection
rates in this group of patients reported elsewhere represent
observational bias because of the infections occurring after
discharge, perpetuated by patients undergoing thesemoreminor,
and often elective, operations having a generally shorter length
of hospital stay. In addition, the “clean” operations entailed
longer and more complex operations than those typically
reported in this category: 32% underwent adhesiolysis and 12%
incisional hernia repair, which are, by definition “re-do” longer
operations and often performed in the acute setting. The overall
proportion of clean operations performed as an emergency was
53%. Together these factors might also have contributed to the
higher than expected infection rate in this group.
All outcome data have been presented in full for the trial. As
per accepted best practice, we primarily undertook an intention
to treat analysis, but it is important to also note that the
sensitivity analysis did not identify any potential difference in
result from treatment cross over.
It is possible that a flaw in the ROSSINI trial has masked a
positive result. Key to this is the blinding process, the use of
the wound edge protection devices, and the measurement of the
endpoint. We instituted an online blinding process in theatre so
the patient and wound assessor were unable to introduce bias.
We compared the effect of use of the devices in high and low
recruiting centres and found no difference between the two
groups. Finally, the trial has identified a high wound infection
rate, which was associated with additional use of health services
to manage the wounds. This was, however, entirely equivalent
between the two arms, both on the resources used and the timing
of the infection treatment. These factors, taken with the large
size and multiple centres in the ROSSINI trial would suggest
the findings are robust.
How wound edge protection devices might
work
The presumptive primary method of action of the device is that
the physical barrier formed by the impervious sheet covering
the cut edges of the wound prevents endogenous and exogenous
pathogens from coming into contact with the cut skin, fat, and
fascia, thereby reducing likelihood of infection. Horiuchi and
colleagues presented evidence supporting this theory, showing
that these devices seem to protect the incision from bacterial
invasion.33 It is therefore possible that a protective effect of the
device could be real, but the pathogens responsible for surgical
site infection could be introduced to the woundwhen the device
is not in place—either on opening the wound before the device
is inserted or on closing after the device has been removed. The
latter would seem more likely as gloves, instruments, and
surroundings will clearly be dirtier. The protocol for our trial
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did not stipulate changing of gloves, instruments, or drapes,
which would not be standard practice in the UK. Evaluation of
this practice in combination with a wound edge protection device
might be worth considering.
We investigated only the single ring variant of the wound edge
protection device. One recent pooled analysis of small single
centre studies indicated a difference in outcomes between single
ring and two ring devices, but there are no head to head data
comparing the different designs.We therefore sought to answer
the broader question of the effect of wound edge protection in
general, but the suggestion that different device designs might
provide greater physical barriers than others could warrant
further investigation.
Implications
Our findings directly challenge the conclusions of numerous
smaller scale, largely single centre trials regarding the efficacy
of device in reducing surgical site infection. We believe that
this outcome is robust and as such feel that practice should
change as the routine use of devices in this role cannot be
recommended. This trial highlights the need for large scale
rigorous and appropriately powered randomised trials to fully
assess surgical interventions or devices before their true efficacy
can be determined.
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Tables
Table 1| Characteristics of patients undergoing laparotomy with and without use of a wound edge protection device (WEPD). Figures are
numbers (percentage) of patients unless specified otherwise
Control (n=373)WEPD (n=376)Characteristic
64.2 (55.5-72.8)66.4 (54.8-74.7)Median (IQR) age (years)
193 (51.7)200 (53.2)Men
26.0 (23.1-29.1)26.5 (23.1-30.0)Median (IQR) BMI
40.0 (35.0-44.0)41.0 (34.0-44.0)Median (IQR) serum albumin concentration
51 (13.7)62 (16.5)Diabetes
57 (15.3)64(17.0)Current smoker
241 (64.6)241 (64.1)Known ongoing malignancy at any site
0.85 (0.73-1)0.81 (0.69-1)Median (IQR) baseline EQ-5D*
Urgency of operation:
183 (49.1)181 (48.1)Elective
117(31.4)117(31.1)Expedited
71 (19.0)75 (20.0)Urgent
2 (0.5)3 (0.8)Immediate
ASA grade:
49 (13.1)36 (9.6)1
186 (49.9)203 (54.0)2
95 (25.5)113 (30.1)3
7 (1.9)4 (1.1)4
1 (0.3)0 (0.00)5
35 (9.4)20 (5.3)Unknown
IQR=interquartile range, BMI=body mass index, EQ-5D=EuroQol health related quality of life score, ASA=American Society of Anaesthesiologists.
*Measured in 359 in WEPD group and 351 in control group.
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Table 2| Procedural characteristics in patients undergoing laparotomy with and without use of a wound edge protection device (WEPD).
Figures are numbers (percentage) of patients unless specified otherwise
Control (n=373)WEPD (n=376)Characteristic
Operation site:
237 (63.5)247 (65.7)Large bowel
48 (12.9)34 (9.0)Small bowel
72 (19.3)77 (20.5)Hepatobiliary
8 (2.1)15 (4.0)Gastric
2 (0.5)1 (0.3)Cholecystectomy
01 (0.3)Vascular
2 (0.5)0Abdominal hysterectomy
4 (1.1)1 (0.3)Unknown
106 (28.4)109 (29.0)Stoma created
Skin prep used:
135 (36.2)136 (36.2)Chlorhexidine
197 (52.8)215 (57.2)Aqueous Betadine (povidone-iodine)
29 (7.8)16 (4.3)Alcoholic Betadine (povidone-iodine)
78 (20.9)42 (11.2)Towels/mops used on wound edges
Degree of contamination:
31 (8.3)24 (6.4)Clean
268 (71.9)275 (73.1)Clean-contaminated
48 (12.9)48 (12.8)Contaminated
25 (6.7)29 (7.7)Dirty
2.73 (2.0-4.0)3.0 (2.0-4.0)Median (IQR) duration of surgery (h)
1 (0-1)1 (0-1)Median (IQR) NNIS index*
Prophylactic antibiotic given:
322 (86.3)321 (85.4)On induction
18 (4.8)25 (6.7)During procedure
Grade of operating surgeon:
280 (75.1)302 (80.3)Consultant
82 (22.0)69 (18.4)Trainee
Grade of surgeon closing fascia:
197 (52.8)186 (49.5)Consultant
157 (42.1)182 (48.4)Trainee
*NNIS index=national nosocomial infections surveillance index.
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Table 3| Primary and secondary endpoints in patients undergoing laparotomy with and without use of a wound edge protection device
(WEPD). Figures are numbers (percentage) of patients unless specified otherwise
P valueEstimate (95% CI)ControlWEPDOutcome
Primary outcome
0.850.97* (0.69 to 1.36)93/366 (25.4)91/369 (24.7)Surgical site infection (SSI) within 30 days
Secondary outcomes
0.950.001§ (−0.04 to 0.05)0.69 (0.30)‡0.69 (0.29)†Mean (SD) EQ-5D
0.821.03¶ (0.88 to 1.19)9 (6 to 14)9 (6 to 15)Median (IQR) length of hospital stay (days)
Degree of wound contamination:
0.431.76* (0.40 to 7.70)7/29 (24.1)8/24 (33.3)Clean
0.760.94* (0.62 to 1.42)63/263 (24.0)61/269 (22.7)Clean-contaminated
0.310.601* (0.23 to 1.63)15/48 (31.3)10/48 (20.8)Contaminated
0.331.85* (0.50 to 6.87)7/25 (28.0)12/28 (42.9)Dirty
IQR=interquartile range, EQ-5D= EuroQol health related quality of life score.
*Odds ratio.
†n=318.
‡n=313.
§Difference in means.
¶Hazard ratio.
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Figures
Fig 1Wound edge protection device being used during surgery via midline laparotomy incision
Fig 2 Trial profile of patients in study of effect of wound edge protection devices during laparotomy
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Fig 3 Rates of surgical site infection by treatment group within 30 days in patients allocated to surgery with use of wound
protection device (WEPD) or standard care
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f4305 doi: 10.1136/bmj.f4305 (Published 31 July 2013) Page 12 of 13
RESEARCH
Fig 4 Subgroup analyses for primary outcome in patients allocated to surgery with use of wound protection device (WEPD)
or standard care
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